Sign In
Buy OCUL
$8.35
+0.0400 (+0.481%)
At Close: Jun 03, 2026
Ocular Therapeutix™ to Present at Two Investor Conferences in September
07:30am, Wednesday, 04'th Sep 2024
BEDFORD, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world
Ocular Therapeutix, Inc. (OCUL) Q2 2024 Earnings Call Transcript
12:53pm, Friday, 09'th Aug 2024
Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Q2 2024 Earnings Conference Call August 7, 2024 8:00 AM ET Company Participants Bill Slattery - VP, IR Pravin Dugel - Executive Chairman, President, CEO Confere
Wall Street Analysts See an 85.43% Upside in Ocular Therapeutix (OCUL): Can the Stock Really Move This High?
10:55am, Friday, 09'th Aug 2024
The consensus price target hints at an 85.4% upside potential for Ocular Therapeutix (OCUL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:30am, Friday, 09'th Aug 2024
BEDFORD, Mass., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the developm
Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates
09:46am, Wednesday, 07'th Aug 2024
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.27 per share a year ago.
Ocular Therapeutix™ Reports Second Quarter 2024 Results
07:10am, Wednesday, 07'th Aug 2024
SOL-R AXPAXLI™ Repeat Dosing Study in Wet AMD Acceptable to FDA as Registrational Trial Enrollment in SOL-1 Continues to Accelerate and SOL-R Actively Enrolling Patients Cash Balance of $459.7M as o
3 Biotech Stocks to Sell in August Before They Crash & Burn
08:00am, Tuesday, 06'th Aug 2024
For investors, one of the most attractive aspects of biotech stocks is their ability to increase in value in a short period of time quickly. After all, it only takes one major breakthrough in clinical
Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024
07:30am, Wednesday, 31'st Jul 2024
BEDFORD, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to improving vision in the real world through the develop
Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study
07:30am, Tuesday, 30'th Jul 2024
SOL-R evaluates repeat AXPAXLI™ dosing for wet age-related macular degeneration (wet AMD) Global non-inferiority study comparing AXPAXLI, dosed every six months, to 2 mg aflibercept every eight week
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Thursday, 18'th Jul 2024
BEDFORD, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people's vision and quality of life through
Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting
08:00am, Wednesday, 10'th Jul 2024
Phase 1 HELIOS study evaluates AXPAXLI™ for non-proliferative diabetic retinopathy (NPDR) Phase 1 HELIOS study evaluates AXPAXLI™ for non-proliferative diabetic retinopathy (NPDR)
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 08'th Jul 2024
BEDFORD, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”, the “Company” ), a biopharmaceutical company committed to enhancing people's vision and qual
This Skyworks Solutions Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
09:13am, Thursday, 20'th Jun 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag
151 subjects enrolled in various stages of loading and randomization in SOL-1 pivotal study of AXPAXLI in wet AMD as of June 7, 2024
Ocular Therapeutix® to Host Investor Day on June 13, 2024
07:30am, Wednesday, 05'th Jun 2024
Company to highlight corporate strategy, clinical data, and development plans for AXPAXLI™ in wet AMD and NPDR
